-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Lenrispodun Phosphate in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lenrispodun Phosphate in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lenrispodun Phosphate in Parkinson's Disease Drug Details: ITI-214 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nivolumab in High-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in High-Grade Glioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nivolumab in High-Grade Glioma Drug Details: Nivolumab (Opdivo, Opdyta) is a...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Rucaparib Camsylate in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rucaparib Camsylate in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rucaparib Camsylate in Solid Tumor Drug Details: Rucaparib camsylate (Rubraca) is...
-
Sector Analysis
Ovarian Cancer Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Ovarian Cancer Market Report Overview The ovarian cancer market across the 7MM was valued at $3.3 billion in 2022. The market will grow at a CAGR of more than 1% from 2022 to 2032. The 7MM includes the US, France, Germany, Italy, Spain, the UK, and Japan. Ovarian cancer is one of the most lethal gynecological cancers worldwide. Approximately 90% of ovarian cancer cases are epithelial, with distinct sites of origin arising from the ovarian surface epithelium or distal fallopian...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nivolumab in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nivolumab in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drug Details: Nivolumab (Opdivo, Opdyta) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Simurosertib in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Simurosertib in Solid Tumor Drug Details: Simurosertib (ZL-2309) is under development for the treatment of...
-
Product Insights
NewNet Present Value Model: Clovis Oncology Inc’s FAP-2286
Empower your strategies with our Net Present Value Model: Clovis Oncology Inc's FAP-2286 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Etrumadenant in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Etrumadenant in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Etrumadenant in Melanoma Drug Details: AB-928 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAA-614 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AAA-614 in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AAA-614 in Colorectal Cancer Drug Details: 3B-201 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAA-614 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AAA-614 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AAA-614 in Solid Tumor Drug Details: 3B-201 is under development for the...